A Phase 2 interventional study of ESK-001 and Placebo in Plaque Psoriasis, sponsored by Alumis Inc. Completed at 53 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Alumis Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 179th largest by enrollment of the 673 interventional ones that give a count, is one of 37 that started in 2022, is one of 200 in phase 2, and was the 665th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 37 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Alumis Inc has 5 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
This study will consist of a 4 week screening period, 12 week treatment period, and a 4 week follow up period for a total of 20 weeks. Each participant will be randomized to receive ESK-001 or placebo daily for 12 weeks. An open label extension study will be available for those patients who complete the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ESK-001 administered as an oral tablet
Drug: ESK-001
ESK-001 administered as an oral tablet
Drug: ESK-001
ESK-001 administered as an oral tablet
Drug: ESK-001
ESK-001 administered as an oral tablet
Drug: ESK-001
ESK-001 administered as an oral tablet
Drug: ESK-001
Placebo administered as an oral tablet
Drug: Placebo
Oral tablet
Oral tablet
To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo
Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score
Time frame: 12 weeks
To Assess the Safety and Tolerability of ESK-001 Dose in Moderate to Severe Psoriasis Patients
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). See Adverse Events section.
Time frame: 12 weeks
To Assess the Response Rate in Static Physician's Global Assessment (sPGA) Score
Proportion of patients achieving an sPGA score of "0" ("cleared") or "1" ("minimal")
Time frame: 12 weeks
To Characterize the Pharmacokinetics (PK) of ESK-001
Plasma concentrations and PK parameters of ESK-001.
Time frame: 14 weeks
| Milestone | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo |
|---|---|---|---|---|---|---|
| Started | 36 | 36 | 39 | 40 | 39 | 38 |
| Completed | 36 | 30 | 33 | 37 | 35 | 33 |
| Not completed | 0 | 6 | 6 | 3 | 4 | 5 |
| Withdrew: Adverse event | 0 | 2 | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 | 3 | 5 |
| Withdrew: Discontinued prior to dosing due to the blood sample logistics | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Subject can't continue with week 16 visit | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: The patient was terminated from the study due to sponsor requirements | 0 | 0 | 0 | 1 | 0 | 0 |
Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score
| Percentage | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo |
|---|---|---|---|---|---|---|
| To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo | 19.4 (8.2 to 36.0) | 33.3 (18.6 to 51.0) | 56.4 (39.6 to 72.2) | 56.4 (36.6 to 72.2) | 64.1 (47.2 to 78.8) | 0 (0.0 to 9.3) |
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). See Adverse Events section.
| Participants | ESK-001 Dose Level 1 | ESK-001 Dose Level 2 | ESK-001 Dose Level 3 | ESK-001 Dose Level 4 | ESK-001 Dose Level 5 | Placebo |
|---|---|---|---|---|---|---|
| To Assess the Safety and Tolerability of ESK-001 Dose in Moderate to Severe Psoriasis Patients | 19 | 14 | 19 | 18 | 25 | 15 |
Proportion of patients achieving an sPGA score of "0" ("cleared") or "1" ("minimal")
| Participants | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo |
|---|---|---|---|---|---|---|
| To Assess the Response Rate in Static Physician's Global Assessment (sPGA) Score | 6 | 14 | 21 | 19 | 23 | 3 |
Plasma concentrations and PK parameters of ESK-001.
| ng/ml | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo |
|---|---|---|---|---|---|---|
| To Characterize the Pharmacokinetics (PK) of ESK-001 | 11.9 ± 12.4 | 33.0 ± 49.9 | 50.7 ± 44.8 | 63.9 ± 44.8 | 174.0 ± 125.0 | 2.9 ± 10.5 |
Collected over Adverse Event data was collected from Screening through end of study (Week 16).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ESK-001 10mg QD | 0/36 (0%) | 1/36 (2.8%) | 8/36 (22.2%) |
| ESK-001 20mg QD | 0/36 (0%) | 0/36 (0%) | 4/36 (11.1%) |
| ESK-001 40mg QD | 0/39 (0%) | 1/39 (2.6%) | 11/39 (28.2%) |
| ESK-001 20mg BID | 0/39 (0%) | 3/39 (7.7%) | 18/39 (46.2%) |
| ESK-001 40mg BID | 0/39 (0%) | 0/39 (0%) | 18/39 (46.2%) |
| Placebo | 0/38 (0%) | 0/38 (0%) | 9/38 (23.7%) |
| Event | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo |
|---|---|---|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 1/36 | 0/36 | 0/39 | 0/39 | 0/39 | 0/38 |
| Tibia fractureInjury, poisoning and procedural complications | 0/36 | 0/36 | 0/39 | 1/39 | 0/39 | 0/38 |
| Coronary artery occlusionCardiac disorders | 0/36 | 0/36 | 0/39 | 1/39 | 0/39 | 0/38 |
| ColitisGastrointestinal disorders | 0/36 | 0/36 | 0/39 | 1/39 | 0/39 | 0/38 |
| EnteritisGastrointestinal disorders | 0/36 | 0/36 | 0/39 | 1/39 | 0/39 | 0/38 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/36 | 0/36 | 1/39 | 0/39 | 0/39 | 0/38 |
| Event | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/36 | 2/36 | 4/39 | 3/39 | 3/39 | 2/38 |
| NasopharyngitisInfections and infestations | 2/36 | 0/36 | 1/39 | 1/39 | 3/39 | 3/38 |
| COVID-19Infections and infestations | 0/36 | 0/36 | 0/39 | 1/39 | 1/39 | 3/38 |
| Upper respiratory tract infectionInfections and infestations | 2/36 | 2/36 | 2/39 | 1/39 | 3/39 | 0/38 |
| Diabetes mellitusMetabolism and nutrition disorders | 2/36 | 0/36 | 0/39 | 1/39 | 0/39 | 0/38 |
| DizzinessNervous system disorders | 0/36 | 0/36 | 1/39 | 2/39 | 0/39 | 0/38 |
| DiarrheaGastrointestinal disorders | 1/36 | 0/36 | 1/39 | 2/39 | 0/39 | 0/38 |
| DyspepsiaGastrointestinal disorders | 0/36 | 0/36 | 0/39 | 2/39 | 0/39 | 0/38 |
| NauseaGastrointestinal disorders | 0/36 | 0/36 | 0/39 | 2/39 | 0/39 | 1/38 |
| AcneSkin and subcutaneous tissue disorders | 0/36 | 0/36 | 2/39 | 0/39 | 2/39 | 0/38 |
| Age, Categorical(Participants) | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 33 | 37 | 35 | 33 | 35 | 206 |
| >=65 years | 3 | 3 | 2 | 5 | 6 | 3 | 22 |
| Age, Continuous(years) | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 48.8 ± 12.7 | 43.9 ± 11.99 | 49.5 ± 10.45 | 47.7 ± 12.52 | 47.9 ± 14.17 | 49.1 ± 11.67 | 47.8 ± 12.3 |
| Sex: Female, Male(Participants) | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 12 | 12 | 13 | 17 | 13 | 7 | 74 |
| Male | 24 | 24 | 26 | 23 | 26 | 31 | 154 |
| Ethnicity (NIH/OMB)(Participants) | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 14 | 13 | 7 | 11 | 13 | 65 |
| Not Hispanic or Latino | 29 | 21 | 26 | 33 | 28 | 24 | 161 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | ESK-001 10mg QD | ESK-001 20mg QD | ESK-001 40mg QD | ESK-001 20mg BID | ESK-001 40mg BID | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Asian | 1 | 2 | 2 | 2 | 2 | 4 | 13 |
| Native Hawaiian or Pacific Islander | 1 | 0 | 0 | 2 | 0 | 0 | 3 |
| Black or African American | 4 | 0 | 1 | 1 | 1 | 3 | 10 |
| White | 30 | 31 | 33 | 34 | 33 | 27 | 188 |
| Other | 0 | 2 | 2 | 1 | 1 | 4 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Jun 2023, 9 months.
Results were first posted in Jul 2024, 1 year after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Envudeucitinib
Alumis Inc